Abstract

AimsIn contrast to all prior AJCC/TNM classifications for differentiated thyroid cancer (DTC) the 8th edition does not take minimal extrathyroidal extension (M-ETE) into consideration for local tumor staging. We therefore aimed to retrospectively assess the specific impact of M-ETE on the outcome of M-ETE patients treated in our clinic.MethodsDTC patients with M-ETE and a follow-up time of ≥ 5 years were included and matched with an identical number of patients without M-ETE, but with equal histopathological tumor subtype and size. The frequency of initially metastatic disease among groups was compared using Fisher’s exact test, the recurrence rate by virtue of log-rank test. Fisher’s exact test and multivariate analysis were used to account for the presence of confounding risk factors.ResultsOne hundred sixty patients (80 matching pairs) were eligible. With other confounding risk factors being equal, the prevalence of N1-/M1-disease at initial diagnosis was comparable among groups (M-ETE: 42.5 %; no M-ETE: 32.5 %; p = 0.25). No differences with regard to the recurrence rate were shown. However, M-ETE patients were treated with external beam radiation therapy more often (16.3 % vs. 1.3 %; p = 0.004) and received higher median cumulative activities of 131I (10.0 vs. 8.0 GBq; p < 0.001).DiscussionAlthough having played a pivotal role for local tumor staging of DTC for decades M-ETE did not increase the risk for metastases at initial diagnosis and the recurrence rate in our cohort. Patients with M-ETE had undergone intensified treatment, which entails a possible confounding factor that warrants further investigation in randomized controlled trials.

Highlights

  • With 53,990 new cases in the USA thyroid cancer is among the most prevalent cancers

  • Information about other risk factors not included into the matching process, such as sex, age > 55, incomplete tumor resection, multifocal tumor lesions and prior treatment (radioactive iodine therapy (RAIT), external beam radiation therapy (EBRT)) was collected and their influence on the results analyzed [17,18,19]

  • The mean patient age was comparable among groups (METE: 48 years, range: 10–78 years; Tumor confined to the thyroid gland (TCT): 45 years, range: 16–75 years)

Read more

Summary

Introduction

With 53,990 new cases in the USA thyroid cancer is among the most prevalent cancers. Women are affected disproportionately and make up 40,900 of new cases [1]. With the advent of the 2017 American Joint Committee on Cancer (AJCC) TNM classification of thyroid cancer a few changes have been implemented: In contrast to previous editions tumors showing minimal extrathyroidal extension (M-ETE) are no longer categorized as pT3 (6th and 7th edition) or pT4 (5th edition), but according to tumor size with the only exception being macroscopic infiltration of the extrathyroidal tissue This caused further downstaging in many patients and is still a topic of debate leading to the proposal of a revision that takes M-ETE into account [9,10,11]. This revision aims at establishing a standardized reporting framework for M-ETE to assess its independent impact on patient prognosis in the future, since prior studies have shown conflicting evidence [12,13,14,15,16]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call